Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Respiratory Syncytial Virus Vaccines: Analysis of the Pre-Marketing Clinical Trial for Immunogenicity in the Population over 50 Years of Age

Georgios Papazisis
* ORCID logo ,
Xanthippi Topalidou
ORCID logo ,
Georgia Gioula
,
Pablo A. González
ORCID logo ,
Susan M Bueno
ORCID logo ,
Alexis M Kalergis
ORCID logo
Version 1 : Received: 20 February 2024 / Approved: 20 February 2024 / Online: 20 February 2024 (14:30:28 CET)

A peer-reviewed article of this Preprint also exists.

Papazisis, G.; Topalidou, X.; Gioula, G.; González, P.A.; Bueno, S.M.; Kalergis, A.M. Respiratory Syncytial Virus Vaccines: Analysis of Pre-Marketing Clinical Trials for Immunogenicity in the Population over 50 Years of Age. Vaccines 2024, 12, 353. Papazisis, G.; Topalidou, X.; Gioula, G.; González, P.A.; Bueno, S.M.; Kalergis, A.M. Respiratory Syncytial Virus Vaccines: Analysis of Pre-Marketing Clinical Trials for Immunogenicity in the Population over 50 Years of Age. Vaccines 2024, 12, 353.

Abstract

Immunosenescence refers to age-related alterations of the immune system function affecting both the humoral and cellular arm of immunity. Understanding immunosenescence and its impact on vaccination of older adults is essential since primary vaccine responses in older individuals can fail to generate complete protection, especially vaccines targeting infections with increased incidence among the elderly, such as the respiratory syncytial virus. Here, we review the clinical trials of both candidate and approved vaccines against respiratory syncytial virus (RSV), which include adults aged ≥50 years, with an emphasis on the evaluation of immunogenicity parameters. Currently, there are 10 vaccine candidates and 2 vaccines approved for the prevention of RSV in the older adult population. The number of registered clinical trials for this age group amounts to 32. Our preliminary evaluation of published results and interim analyses of the RSV vaccine clinical trials indicates efficacy in older adult participants, demonstrating immunity levels that closely resemble those of younger adult participants.

Keywords

immunosenescence; inflammaging; vaccinology; respiratory syncytial virus; aging; elderly; clinical trials

Subject

Medicine and Pharmacology, Medicine and Pharmacology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.